Academic Journal
Q1JAMA Oncology
About JAMA Oncology
JAMA Oncology is a scholarly journal published by American Medical Association. SCImago 2025 places it in Q1 with an SJR of 7.399 and an H-index of 208.
Its listed coverage is 2015-2026 and its research categories include Cancer Research (Q1); Oncology (Q1). The 2025 dataset reports 308 documents and 9717 citations across the latest three-year reporting window.
JAMA Oncology, a renowned journal published by the American Medical Association (AMA), is one of the leading platforms for cutting-edge research in the field of oncology. This prestigious peer-reviewed medical journal is dedicated to advancing the science of cancer treatment, prevention, and care through high-quality clinical and translational research. JAMA Oncology plays a pivotal role in the oncology community, offering readers an up-to-date understanding of the latest developments in cancer therapy, diagnostics, and the overall management of cancer patients.
What is JAMA Oncology?
JAMA Oncology is part of the JAMA Network, which includes a collection of journals focusing on various medical specialties. Established in 2015, the journal has quickly gained recognition for its rigorous research and its ability to shape cancer care practices worldwide. The journal publishes original research articles, systematic reviews, meta-analyses, and commentary pieces, all aimed at improving the understanding of cancer and enhancing patient outcomes.
Scope of JAMA Oncology
The journal covers a broad spectrum of topics in oncology, including but not limited to:
-
Cancer Epidemiology: Understanding the distribution and determinants of cancer across populations.
-
Cancer Treatment and Therapy: Studies on innovative cancer treatments, including chemotherapy, immunotherapy, targeted therapies, and precision medicine.
-
Cancer Prevention: Research on lifestyle factors, screening methods, and early detection techniques aimed at preventing cancer.
-
Oncology Drug Development: Reviews and findings on the development of novel drugs, biologics, and their clinical applications in treating various types of cancer.
-
Palliative Care: Addressing the needs of cancer patients through end-of-life care and symptom management.
-
Survivorship: Focusing on improving the quality of life for cancer survivors and addressing long-term health issues following cancer treatment.
JAMA Oncology publishes articles that not only impact medical research but also influence clinical practice and healthcare policy, making it a critical resource for oncologists, researchers, healthcare providers, and policy-makers.
Impact of JAMA Oncology in Cancer Research
One of the significant contributions of JAMA Oncology is its role in disseminating groundbreaking clinical trials and data. Its publications have a far-reaching impact on the oncology field, influencing treatment protocols and the standards of care in cancer management. Researchers and oncologists rely on the findings published in JAMA Oncology to make informed decisions about cancer therapies, improving patient outcomes and contributing to the ongoing fight against cancer.
The journal is also instrumental in introducing new perspectives on cancer prevention and early detection. Its comprehensive reviews and studies provide insights into how healthcare systems and individuals can work together to reduce cancer risk and ensure early diagnosis.
Access and Submission Process
JAMA Oncology is accessible to a global audience, offering both print and online access to its content. Researchers and clinicians can subscribe to receive updates or visit the journal's website to explore recent issues and articles.
For researchers wishing to submit their work to JAMA Oncology, the submission process is straightforward. Authors are required to submit their manuscripts through the journal’s online submission system, ensuring that their research undergoes a thorough peer-review process before publication.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
JAMA Oncology, a leading peer-reviewed medical journal, plays a pivotal role in disseminating cutting-edge research in the field of oncology. As an authoritative source, it focuses on clinical and experimental studies, providing oncologists, researchers, and healthcare professionals with the latest insights into cancer treatment, prevention, and diagnostics. Published by the American Medical Association, JAMA Oncology has a broad scope that includes a variety of important topics within the realm of cancer care, addressing both the scientific community and the broader healthcare sector.
1. Clinical Oncology Research
One of the primary focuses of JAMA Oncology is the publication of clinical trials and research studies. These articles contribute significantly to the understanding of new cancer treatments, therapies, and clinical practices. From novel chemotherapy regimens to immunotherapy breakthroughs, JAMA Oncology features research that directly influences patient care and clinical decision-making. The journal covers a wide range of cancers, including but not limited to breast cancer, lung cancer, colorectal cancer, and hematologic malignancies.
2. Cancer Prevention and Screening
Beyond treatment, JAMA Oncology addresses cancer prevention and early detection. Research on screening methodologies, such as mammography, colonoscopy, and genetic testing, plays a crucial role in reducing cancer mortality rates. The journal regularly publishes studies that explore risk factors, preventive measures, and lifestyle interventions that can help in minimizing cancer incidence across various populations. These articles are vital for healthcare providers aiming to implement evidence-based strategies for cancer prevention and early diagnosis.
3. Cancer Genetics and Molecular Biology
Another key area of focus within JAMA Oncology is the exploration of cancer genetics and molecular biology. In recent years, the journal has provided valuable insights into the genetic mutations and molecular pathways that drive cancer progression. These studies are essential in understanding how cancer cells evolve and how treatments can be tailored to target specific genetic alterations. JAMA Oncology also discusses advancements in precision medicine, where targeted therapies based on genetic profiling offer personalized treatment options for patients.
4. Oncological Innovations and Therapies
JAMA Oncology publishes content related to innovative cancer therapies and treatments. From cutting-edge immunotherapies to advancements in chemotherapy and radiation treatment techniques, the journal highlights studies that introduce novel approaches to managing cancer. The exploration of CAR T-cell therapies, checkpoint inhibitors, and other immune-based therapies has transformed cancer treatment, making JAMA Oncology an essential resource for professionals seeking the latest developments in the field.
5. Palliative Care and Survivorship
Cancer care does not end with treatment. The journal also addresses the aspects of palliative care and survivorship, which are vital to improving the quality of life for cancer patients. Topics related to pain management, mental health, and the psychosocial aspects of cancer care are regularly featured. Additionally, JAMA Oncology explores the long-term effects of cancer treatment and how survivors can be supported in managing their health post-treatment.
6. Health Policy and Disparities in Cancer Care
The journal is also committed to addressing the broader societal issues related to cancer, including health policy, healthcare disparities, and access to care. Articles examining the economic burden of cancer treatment, access to cancer care for underserved populations, and policies influencing cancer research and patient outcomes are critical components of JAMA Oncology. These studies aim to inform public health policies and improve cancer care on a global scale.
Recent Research Articles
Latest publications matched automatically by ISSN.
Concerns Regarding Patient Burden and Intraperitoneal Port Use in the DRAGON-01 Trial—Reply
Chao Yan, Zhongyin Yang, Zhenggang Zhu
2026-09-03 · DOI: 10.1001/jamaoncol.2026.3544Incidental SDHA Variant Diagnosis—A Cancer Geneticist’s Viewpoint as a Patient
Erica H. Bell
2026-09-03 · DOI: 10.1001/jamaoncol.2026.3316Man With Undifferentiated Shock and Hypoxemic Respiratory Failure
Katerina Dangas, Tarun N. Ramesh, Michael Gillette
2026-09-03 · DOI: 10.1001/jamaoncol.2026.3322Neoadjuvant Anbenitamab and HB1801 in ERBB2 -Positive Breast Cancer
Junjie Li, Tong Liu, Ke-Da Yu, Huawei Yang et al.
2026-09-03 · DOI: 10.1001/jamaoncol.2026.3329Bicistronic CD19/CD22 CAR T-Cell Therapy in Pediatric B-Cell Acute Lymphoblastic Leukemia
Xinyu Wan, Yanjing Tang, Jiaoyang Cai, Lili Song et al.
2026-09-03 · DOI: 10.1001/jamaoncol.2026.3460CAR T-Cell Therapy in Acute Lymphoblastic Leukemia—Is Limited Persistence Enough?
Giovanna Lucchini, Giorgio Ottaviano, Andrea Biondi
2026-09-03 · DOI: 10.1001/jamaoncol.2026.3016Concerns Regarding Patient Burden and Intraperitoneal Port Use in the DRAGON-01 Trial
Yohei Kishi, Yurika Saito, Anri Inumaru
2026-09-03 · DOI: 10.1001/jamaoncol.2026.3541Supplements and Wellness Products During Cancer Care
Kaiwen Wang, Dylan Singhi, Eric K. Singhi
2026-08-27 · DOI: 10.1001/jamaoncol.2026.2724Adult T-Cell Leukemia/Lymphoma and Maternal Screening—Reply
Paulo S. Pinheiro
2026-08-27 · DOI: 10.1001/jamaoncol.2026.3313Adult T-Cell Leukemia/Lymphoma and Maternal Screening
Yue Chang
2026-08-27 · DOI: 10.1001/jamaoncol.2026.3310Systemic Therapy Considerations in Older Adults With Early-Stage Breast Cancer
Claire E. Smith, Sarah L. Sammons, Christina A. Minami, Mina S. Sedrak et al.
2026-08-27 · DOI: 10.1001/jamaoncol.2026.3121Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients
Xiaoyu Liu, Xiaoyi Xu, Z John Lu, Ya-Chen Tina Shih et al.
2026-08-27 · DOI: 10.1001/jamaoncol.2026.3128Recent Food and Drug Administration Decisions and the Future of the Development of Cancer Drugs in the US
Gilberto Lopes
2026-08-20 · DOI: 10.1001/jamaoncol.2026.2843Concerns Regarding NSCLC Immunoradiotherapy Study Interpretability—Reply
Han Zhou, Teddy Tai Loy Lee, Feng-Ming (Spring) Kong
2026-08-20 · DOI: 10.1001/jamaoncol.2026.2924Concerns Regarding NSCLC Immunoradiotherapy Study Interpretability
Jie Xiang
2026-08-20 · DOI: 10.1001/jamaoncol.2026.2918Academy of QI—Learning Leadership by Quality Improvement
Eric Ford, Cassandra Stambaugh
2026-08-20 · DOI: 10.1001/jamaoncol.2026.2940Federal and Industry Sponsorship in US Cancer Clinical Trials
Joseph M. Unger, Hong Xiao, Michael L. LeBlanc, Dawn L. Hershman et al.
2026-08-20 · DOI: 10.1001/jamaoncol.2026.3026Racial and Ethnic Disparities in US Colorectal Cancer Mortality by County, Sex, and Age
Paula D. Strassle, Christian S. Alvarez, Laura Dwyer-Lindgren
2026-08-20 · DOI: 10.1001/jamaoncol.2026.3194Concerns Regarding NSCLC Immunoradiotherapy Study Interpretability
Mandy Jongbloed, Dirk K. M. De Ruysscher, Lizza E. L. Hendriks
2026-08-20 · DOI: 10.1001/jamaoncol.2026.2921Concerns Regarding NSCLC Immunoradiotherapy Study Interpretability
Chang Yue
2026-08-20 · DOI: 10.1001/jamaoncol.2026.2915Reviews
Community Reviews
Version History
April 14, 2025 at 4:57 pm
April 14, 2025